JUPITER, Fla., Jan. 29, 2014 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that the expansion of its research laboratory in The Netherlands is now complete.
Dyadic's Chief Operating Officer, Danai Brooks, stated, "Commercial interest in Dyadic's C1 expression technology has increased with new end markets, such as biopharmaceuticals, and new customers, such as BASF. By investing in our R&D capabilities, we are able to expand our new product development pipeline, take on additional projects with our strategic partners, and invest in strengthening the technology platform. We are extremely excited about several new projects commencing in 2014 and we expect to provide additional details about these projects in the coming weeks."
Floor space at Dyadic Netherlands has significantly increased, allowing for the installation of a wide range of state-of-the-art research equipment including a new fermentation lab. In addition, the expansion will facilitate the housing of new scientists who were recently hired for the new C1-technology projects. Dyadic increased its scientific staff by 40% in 2013 and plans to continue hiring molecular biologists, enzymologists and fermentation specialists through 2014.
Wim van der Wilden, General Manager of Dyadic Netherlands, added, "The expansion was necessary to meet the projected needs of the market. In the past year we have seen a growing interest for our C1 system with commercial and academic parties. Having these state-of-the-art facilities, in combination with a larger scientific staff, will allow us to take on additional projects while broadening our services to the market. This expansion strengthens the position of Dyadic Netherlands as a preferred partner for companies throughout the biotechnology industry who want to leverage Dyadic's C1 technology, or who do not have the requisite in-house research skills."
A grand opening ceremony will be held on March 6, 2014 where customers, suppliers, partners and investors will be invited to tour the facility in Wageningen.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
SOURCE Dyadic International, Inc.